Department of Coloproctology, Hospital Moinhos de Vento, Porto Alegre 90035-902, RS, Brazil.
Department of Surgery, Hospital de Clínicas de Passo Fundo, Passo Fundo 99010-260, RS, Brazil.
World J Gastroenterol. 2020 Nov 14;26(42):6572-6581. doi: 10.3748/wjg.v26.i42.6572.
One of the most challenging phenotypes of Crohn's disease is perianal fistulizing disease (PFCD). It occurs in up to 50% of the patients who also have symptoms in other parts of the gastrointestinal tract, and in 5% of the cases it occurs as the first manifestation. It is associated with severe symptoms, such as pain, fecal incontinence, and a significant reduction in quality of life. The presence of perianal disease in conjunction with Crohn's disease portends a significantly worse disease course. These patients require close monitoring to identify those at risk of worsening disease, suboptimal biological drug levels, and signs of developing neoplasm. The last 2 decades have seen significant advancements in the management of PFCD. More recently, newer biologics, cell-based therapies, and novel surgical techniques have been introduced in the hope of improved outcomes. However, in refractory cases, many patients face the decision of having a stoma made and/or a proctectomy performed. In this review, we describe modern surgical management and the most recent advances in the management of complex PFCD, which will likely impact clinical practice.
克罗恩病最具挑战性的表型之一是肛周瘘管病(PFCD)。它发生在多达 50%的同时存在胃肠道其他部位症状的患者中,在 5%的情况下,它是作为首发表现出现的。它与严重的症状相关,如疼痛、粪便失禁和生活质量的显著降低。肛周疾病与克罗恩病并存预示着疾病病程显著恶化。这些患者需要密切监测,以识别那些有疾病恶化风险、生物药物水平不理想和出现肿瘤迹象的患者。过去 20 年来,PFCD 的治疗取得了重大进展。最近,新型生物制剂、基于细胞的治疗方法和新型手术技术已被引入,以期改善治疗效果。然而,在难治性病例中,许多患者面临着需要造口和/或直肠切除术的决定。在这篇综述中,我们描述了 PFCD 的现代手术治疗和复杂 PFCD 管理的最新进展,这可能会影响临床实践。